U.S. markets open in 9 hours 1 minute
  • S&P Futures

    3,296.50
    -2.75 (-0.08%)
     
  • Dow Futures

    27,227.00
    +84.00 (+0.31%)
     
  • Nasdaq Futures

    11,095.00
    -54.50 (-0.49%)
     
  • Russell 2000 Futures

    1,487.50
    -1.30 (-0.09%)
     
  • Crude Oil

    39.55
    -0.05 (-0.13%)
     
  • Gold

    1,892.90
    -14.70 (-0.77%)
     
  • Silver

    23.83
    -0.70 (-2.85%)
     
  • EUR/USD

    1.1681
    -0.0029 (-0.25%)
     
  • 10-Yr Bond

    0.6640
    -0.6710 (-100.00%)
     
  • Vix

    26.86
    -27.78 (-100.00%)
     
  • GBP/USD

    1.2719
    -0.0017 (-0.13%)
     
  • USD/JPY

    105.0750
    +0.1510 (+0.14%)
     
  • BTC-USD

    10,485.68
    -56.08 (-0.53%)
     
  • CMC Crypto 200

    222.28
    +8.53 (+3.99%)
     
  • FTSE 100

    5,829.46
    +25.17 (+0.43%)
     
  • Nikkei 225

    23,283.56
    -76.74 (-0.33%)
     

Concordia, Par Pharmaceutical settle anti-competition charges -U.S. FTC

WASHINGTON, Aug 18 (Reuters) - Concordia Pharmaceuticals Inc and Par Pharmaceutical Inc have settled charges they unlawfully agreed not to compete in the sale of a generic version of Kapvay, a drug used to treat attention deficit hyperactivity disorder, the U.S. Federal Trade Commission said on Tuesday.

The FTC had alleged Concordia, a unit of Concordia Healthcare Corp, had agreed not to sell a generic version of the drug in exchange for a share of Par's revenues. Par is a subsidiary of Par Pharmaceutical Holdings Inc..

Concordia and Par were the only two firms permitted by U.S. regulators to sell a generic version of Kapvay. The settlement bars them from enforcing anticompetitive provisions of their agreement, including the profit-sharing provision, the FTC said.

(Reporting by Timothy Ahmann; Editing by Sandra Maler)